共 50 条
- [1] A phase Ib/II study to assess the safety and efficacy of PM8002/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2024, 35 : S361 - S361Wu, J.Zhang, J.Tong, Z.Zhang, Q.Wang, Y.Cheng, Q.Chen, X.Li, Z.Yin, Y.Du, Y.Meng, Y.
- [2] A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Wu, JiongZhang, JianTong, ZhongshengWang, YongshengZhang, QingyuanCheng, QiaoChen, Xin
- [3] A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)ANNALS OF ONCOLOGY, 2023, 34 : S1062 - S1062Cheng, Y.Qin, Z.Meng, X.Xu, F.Wang, Y.Yao, Y.Fang, J.Zhao, Y.
- [4] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trialNature Communications, 15Qiao LiJiaxuan LiuQingyuan ZhangQuchang OuyangYang ZhangQiang LiuTao SunFeng YeBaochun ZhangSummer XiaBangyong ZhangBinghe Xu
- [5] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trialNATURE COMMUNICATIONS, 2024, 15 (01)Li, QiaoLiu, JiaxuanZhang, QingyuanOuyang, QuchangZhang, YangLiu, QiangSun, TaoYe, FengZhang, BaochunXia, SummerZhang, BangyongXu, Binghe
- [6] Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Guo, YeGuo, JunCheng, YingWang, ZhenLi, YongshengLv, DongqingYin, YongmeiLi, GuilingWu, LingyingHuang, YiWei, ShuqingShen, LinDuan, HuaxinCui, JiuweiLuo, HongLi, XiuminNan, KejunWang, ChunyanLuo, Su-XiaLiu, Ruonan
- [7] A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLCJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Wu, ChunjiaoLv, DongqingCui, JiuweiWang, ZhenZhao, HuiDuan, HuaxinDuan, PingYin, YongmeiPan, YueyinLiu, Fu-NanKong, ChuizeZhang, JianLi, YongshengHan, XinpengLiu, BaogangHe, LijieQin, ZhiquanWu, TaoJi, MeiCheng, Ying
- [8] Efficacy, Safety, and Tolerability of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC):Final results of the Phase II trialCANCER RESEARCH, 2023, 83 (05)Li, QiaoZhang, QingyuanZhang, YueOuyang, QuchangLiu, QiangSun, TaoYe, FengZhang, BaochunXu, TingXia, SummerZhang, KarlZhang, BangyongXu, Binghe
- [9] PHASE I SAFETY AND PRELIMINARY EFFICACY OF PM8002 IN SUBJECTS WITH ADVANCED SOLID TUMORS, A BISPECIFIC ANTIBODY TARGETING PD-L1 AND VEGF-AJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A758 - A758Guo, YeLuo, SuxiaQin, YanruYin, YongmeiLi, GuilingWang, JingfenLi, YongshengGuo, JunZhang, FengHuang, YiLuo, HongLv, DongqingYing, ChengWang, ChunyanChou, Chuan-ChuGong, ChundanChang, RuixiaLiu, JingHu, Guoqiang
- [10] Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).CANCER RESEARCH, 2021, 81 (13)Xu, BingheLi, QiaoZhang, QingyuanZhang, YueOuyang, QuchangZhang, YangLiu, QiangSun, TaoXu, JuneYang, JingYang, YueLuo, XinKong, PaulXu, Ting